Direct-to-consumer health-care startup Ro said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly. Ro will ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.